SRTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sensus Healthcare Inc (SRTS) is not a strong buy at the moment for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. While the technical indicators show some bullish trends, the company's financial performance has significantly deteriorated, and there are no strong positive catalysts or recent news to support a buy decision. Additionally, there are no proprietary trading signals indicating a strong buy opportunity today.
The MACD is positive and contracting, RSI is neutral at 60.821, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 4.532) with a pre-market price of 4.44. However, no clear breakout or strong momentum is evident.
Analysts have a Buy rating with price targets of $6 and $7.50, indicating potential upside. The stock has an 80% chance of gaining 9.16% in the next week and 19.86% in the next month based on historical patterns.
The company's Q4 2025 financials showed a sharp decline in revenue (-62.20% YoY), net income (-304.85% YoY), and EPS (-311.11% YoY). Gross margin also dropped significantly. No recent news or significant insider/hedge fund activity is present to support a strong buy case.
In Q4 2025, revenue dropped to $4.94M (-62.20% YoY), net income fell to -$3.17M (-304.85% YoY), and EPS declined to -0.19 (-311.11% YoY). Gross margin decreased to 38.41% (-29.38% YoY), indicating a challenging financial position.
Analysts maintain a Buy rating but have lowered price targets recently. Alliance Global set a $7.50 target, citing strong revenue growth potential from new reimbursement codes in 2026. Maxim lowered its target to $6 from $8 due to weak Q4 results and lack of sales from a major customer.
